Hongwei Lv
- Molecular Biology top 10%
- Cancer Research top 2%
- Oncology top 10%
- Biomedical Engineering top 10%
- Immunology top 10%
- Topics
- Cancer Cells and Metastasis (6 papers)MicroRNA in disease regulation (4 papers)Cancer Immunotherapy and Biomarkers (4 papers)
- Partner nations
- ChinaIsraelSouth Korea
In The Last Decade
Hongwei Lv
28 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Molecular Biology 1.2k
- Cancer Research 883
- Oncology 332
- Biomedical Engineering 312
- Immunology 281
Countries citing papers authored by Hongwei Lv
This map shows the geographic impact of Hongwei Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongwei Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongwei Lv more than expected).
Fields of papers citing papers by Hongwei Lv
This network shows the impact of papers produced by Hongwei Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongwei Lv. The network helps show where Hongwei Lv may publish in the future.
Co-authorship network of co-authors of Hongwei Lv
This figure shows the co-authorship network connecting the top 25 collaborators of Hongwei Lv. A scholar is included among the top collaborators of Hongwei Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongwei Lv. Hongwei Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancerbreakdown → | 62 |
| 6 | 86 | |
| 7 | 4 | |
| 8 | 4 | |
| 9 | 11 | |
| 10 | 0 | |
| 11 | 179 | |
| 12 | Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancerbreakdown → | 779 |
| 13 | 12 | |
| 14 | 7 | |
| 15 | 23 | |
| 16 | 36 | |
| 17 | 65 | |
| 18 | 9 | |
| 19 | 179 | |
| 20 | 5 |
About Hongwei Lv
Hongwei Lv is a scholar working on Cancer Research, Oncology and Immunology, having authored 30 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (6 papers), MicroRNA in disease regulation (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Cancer Research (883 citations), Molecular Biology (1.2k citations) and Cell Biology (221 citations). Hongwei Lv has collaborated with scholars based in China, Israel and South Korea. Frequent co-authors include Guishuai Lv, Hongyang Wang, Wen Yang, Tian Fang, Changzheng Wang, Qin Han, Liang Tang, Shanhua Tang, Linna Guo and Le‐Xing Yu. Their work appears in journals such as Nature Communications, Cell Metabolism and Science Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.